These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 18698875)

  • 1. Riluzole in the treatment of mood and anxiety disorders.
    Pittenger C; Coric V; Banasr M; Bloch M; Krystal JH; Sanacora G
    CNS Drugs; 2008; 22(9):761-86. PubMed ID: 18698875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Bellingham MC
    CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder.
    Mathew SJ; Price RB; Mao X; Smith EL; Coplan JD; Charney DS; Shungu DC
    Biol Psychiatry; 2008 May; 63(9):891-8. PubMed ID: 18028881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label trial of riluzole in generalized anxiety disorder.
    Mathew SJ; Amiel JM; Coplan JD; Fitterling HA; Sackeim HA; Gorman JM
    Am J Psychiatry; 2005 Dec; 162(12):2379-81. PubMed ID: 16330605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
    Machado-Vieira R; Manji HK; Zarate CA
    Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder.
    Grant P; Song JY; Swedo SE
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):309-15. PubMed ID: 20807069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate modulators as novel interventions for mood disorders.
    Mathew SJ; Keegan K; Smith L
    Braz J Psychiatry; 2005 Sep; 27(3):243-8. PubMed ID: 16224615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression.
    Park LT; Lener MS; Hopkins M; Iadorola N; Machado-Vieira R; Ballard E; Nugent A; Zarate CA
    J Clin Psychopharmacol; 2017 Jun; 37(3):355-358. PubMed ID: 28338546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Coric V; Taskiran S; Pittenger C; Wasylink S; Mathalon DH; Valentine G; Saksa J; Wu YT; Gueorguieva R; Sanacora G; Malison RT; Krystal JH
    Biol Psychiatry; 2005 Sep; 58(5):424-8. PubMed ID: 15993857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
    Zarate CA; Quiroz JA; Singh JB; Denicoff KD; De Jesus G; Luckenbaugh DA; Charney DS; Manji HK
    Biol Psychiatry; 2005 Feb; 57(4):430-2. PubMed ID: 15705360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole: what it does to spinal and brainstem neurons and how it does it.
    Cifra A; Mazzone GL; Nistri A
    Neuroscientist; 2013 Apr; 19(2):137-44. PubMed ID: 22596264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder.
    Grant P; Lougee L; Hirschtritt M; Swedo SE
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):761-7. PubMed ID: 18315448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool.
    Lazarevic V; Yang Y; Ivanova D; Fejtova A; Svenningsson P
    Neuropharmacology; 2018 Dec; 143():38-48. PubMed ID: 30222983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riluzole suppresses post-sigh, but not spontaneous apnoeas during sleep in rats.
    Radulovacki M; Pavlovic S; Rakic A; Janelidze M; Shermulis L; Carley DW
    J Pharm Pharmacol; 2001 Nov; 53(11):1555-9. PubMed ID: 11732759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
    Jankovic J; Hunter C
    Parkinsonism Relat Disord; 2002 Mar; 8(4):271-6. PubMed ID: 12039422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond monoamines: glutamatergic function in mood disorders.
    Kugaya A; Sanacora G
    CNS Spectr; 2005 Oct; 10(10):808-19. PubMed ID: 16400244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study.
    Abdallah CG; Coplan JD; Jackowski A; Sato JR; Mao X; Shungu DC; Mathew SJ
    Neurosci Lett; 2012 Nov; 530(1):103-7. PubMed ID: 23043888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.